Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. demonstrates a strong potential for market success driven by the impressive efficacy profile of its lead program, TARA-002, which shows 100% durability and an 80% salvage rate upon re-induction. Additionally, the positive outcomes from clinical trials surrounding its intravenous choline chloride therapy highlight significant improvements in liver health, further strengthening the company’s position in treating rare diseases. With a robust safety profile and evolving competitive landscape, Protara is well-positioned to achieve wide adoption and sustained growth in its therapeutic offerings.

Bears say

Protara Therapeutics Inc reported a significant net loss of $12.7 million, translating to a loss of $0.48 per share in the fourth quarter of 2024, which raises concerns about the company's financial stability. Despite promising early signals from its TARA-002 program, the company's stock is trading at a steep discount relative to competitors, indicating potential undervaluation issues that may stem from market skepticism regarding future performance. Additionally, the competitive landscape in the NMIBC market, along with safety concerns regarding choline levels in patients, presents challenges that could hinder Protara's ability to effectively advance its therapies and improve investor confidence.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.